Showing 24 out of 31 results
The ACCC pilots its first ‘effect test’ in misuse of market power proceedings
On 6 December 2019, the ACCC launched its first enforcement proceedings under the new ‘effects test’ prohibition on misuse of market power. The …
ACCC issues guidance on competition risks in IP transactions: Beware the inadvertent cartel
The ACCC has issued final Guidelines on how Australia’s competition laws will apply to intellectual property assignments and licences following the …
Is your Australian trade mark culturally appropriate?
In the globalised world in which we live, culture is certainly trending, but brands need to keep cultural sensitivities in mind to avoid marketing …
Australian Patent Update: three key changes underway
Last August we considered IP Australia’s Exposure Draft outlining the potential impact of proposed changes to the Patents Act 1990 (Cth). Following the …
HERBERT SMITH FREEHILLS ADVISES STRIDES ON DISPOSAL OF AUSTRALIAN PHARMACEUTICAL BUSINESS
International law firm Herbert Smith Freehills has advised Strides Pharma Science Limited, an Indian listed pharmaceuticals company, on the AU$394 …
What’s the damage? – The Federal Court’s decision in Sigma v Wyeth
Justice Jagot’s recent decision (of more than 400 pages) in Sigma v Wyeth1 is an Australian first. The judgment considers the damages payable pursuant to …
ACCC to up the ante in consumer protection matters
The ACCC recently released its Annual Report for the 2017/2018 financial year.1 As well as looking back at the ACCC’s performance over the year, for …
Pfizer beats the ACCC again – implications for pharma
The Full Court of the Federal Court of Australia has dismissed an appeal by the ACCC against an earlier judgment in relation to pharmaceutical company …
Employment and Workplace Relations in Australia Guide 2018
The 2018 edition of our annual Guide to Employment and Workplace Relations in Australia has been published, providing a comprehensive and practical …
As the medical cannabis sector heats up, the Australian Securities Exchange issues a reminder of its listing requirements
The Australian Securities Exchange’s rigorous listing requirements will contribute to the growing interest in ASX-listed cannabis companies on the part …
Pre-trial discovery of manufacturing process information for Etanercept biosimilar allowed
In this week’s important decision of Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCAFC 193, the Full Court of the Federal Court of …
How to reform Australia’s pharmacy sector
The panel reviewing Australia's pharmacy sector is due to issue its interim report shortly.It has received a lot of advice from the sector, but it may be …
Showing 24 out of 31 results
View more